Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that ER positive, HER2-positive, and PR positive status confers therapeutic sensitivity to Neratinib in patients with Invasive Breast Carcinoma.
Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.
This statement is based on a regulatory approval from the Health Canada:
NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |